Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

109.03
-4.0000-3.54%
Post-market: 109.030.00000.00%16:32 EST
Volume:869.19K
Turnover:94.57M
Market Cap:6.26B
PE:-70.58
High:114.99
Open:114.99
Low:106.43
Close:113.03
52wk High:161.78
52wk Low:73.16
Shares:57.43M
Float Shares:55.40M
Volume Ratio:1.19
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5448
EPS(LYR):-2.7746
ROE:-12.19%
ROA:-5.74%
PB:8.14
PE(LYR):-39.30

Loading ...

Earning Preview: Glaukos Q4 revenue is expected to increase by 35.42%, and institutional views are broadly bullish

Earnings Agent
·
Feb 10

Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS) and Avantor (AVTR)

TIPRANKS
·
Yesterday

Glaukos assumed with an Outperform at William Blair

TIPRANKS
·
Jan 30

Glaukos Is Maintained at Buy by BTIG

Dow Jones
·
Jan 29

Glaukos price target raised to $131 from $123 at BTIG

TIPRANKS
·
Jan 29

Wells sees potential upside after Glaukos’ iDose repeat dosing label approved

TIPRANKS
·
Jan 28

Glaukos Corp : Btig Raises Target Price to $131 From $123

THOMSON REUTERS
·
Jan 28

BUZZ-U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker International

Reuters
·
Jan 28

Shares of Glaukos Rise 4.2% Premarket After FDA Allows Repeat Use of Glaucoma Implant

THOMSON REUTERS
·
Jan 28

BUZZ-Glaukos rises as FDA allows repeat use of glaucoma implant

Reuters
·
Jan 28

FDA Approves Glaukos Labeling Supplement Allowing iDose TR Re-Administration

Reuters
·
Jan 28

Glaukos Corp - Idose Tr Shows Favorable Long-Term Corneal Safety Profile

THOMSON REUTERS
·
Jan 28

Glaukos Corp - Idose Tr Second Administration Safe and Well-Tolerated

THOMSON REUTERS
·
Jan 28

Glaukos Announces US FDA Approval of Nda Supplement Allowing for Re-Administration of Idose® Tr

THOMSON REUTERS
·
Jan 28

Glaukos (GKOS) Receives a Buy from BTIG

TIPRANKS
·
Jan 27

Stifel Nicolaus Remains a Buy on Glaukos (GKOS)

TIPRANKS
·
Jan 26

Glaukos President and COO Joseph E. Gilliam Reports Disposal of Common Shares

Reuters
·
Jan 24

Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors

TIPRANKS
·
Jan 22

Glaukos CEO Thomas William Burns Reports Disposal of Common Shares

Reuters
·
Jan 21

Glaukos Corporation to Release Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Jan 20